Great Point Partners, a Greenwich-based investment firm focused exclusively on the health care industry, has acquired Lyocontract GmbH, a premium independent drug product contract development and manufacturing organization (CDMO) based in Ilsenburg, Germany.
 
Founded in 2007, Lyocontract provides aseptic liquid filling, lyophilization, and packaging services. Compliant with the European Union’s Annex 1 standards, the Company specializes in the production of liquid and freeze-dried parenteral drugs, distributing globally for both clinical and commercial use.
 
“Lyocontract has an opportunity to further scale and broaden its offerings and expand its global capabilities at a time when there is growing demand for lyophilization services,” said Noah Rhodes, Managing Director and Head of Private Equity at GPP. “We look forward to leveraging our experience strengthening successful CDMOs to solidify Lyocontract’s position as a global industry leader.”
 
“GPP’s capital resources, paired with the firm’s strategic and tactical counsel, will be invaluable in helping us further scale Lyocontract’s contract manufacturing capabilities and distribution reach,” said Dr. Tino Galgon, CEO of Lyocontract. “We look forward to our next chapter as we embark on an exciting phase of growth to deliver products of the highest quality.”

Related News